Idiopathic Pulmonary Fibrosis Market Size in 7MM was USD 3,167 million in 2021

The Idiopathic Pulmonary Fibrosis market is expected to grow significantly owing to the use of Idiopathic Pulmonary Fibrosis inhibitors in statin-intolerant patients, promising future strategies of Idiopathic Pulmonary Fibrosis, and implications of Idiopathic Pulmonary Fibrosis in broader therapy area. The Idiopathic Pulmonary Fibrosis market companies are working like FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.

The Idiopathic Pulmonary Fibrosis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Idiopathic Pulmonary Fibrosis market size from 2019 to 2032. The Report also covers current Idiopathic Pulmonary Fibrosis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Idiopathic Pulmonary Fibrosis Market Report

• The Idiopathic Pulmonary Fibrosis market size in seven major markets was USD 3,167 million in 2021

• The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019-2032).

• Idiopathic Pulmonary Fibrosis companies working in the market are FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.

To discover which therapies are expected to grab the major Idiopathic Pulmonary Fibrosis Market share, click here for Idiopathic Pulmonary Fibrosis Market Research Report @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle-aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as 'Diffuse Parenchymal Lung Diseases,' which is characterized by a broader umbrella of 'Interstitial Lung Diseases (IDLs).

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM
• Idiopathic Pulmonary Fibrosis Diagnosed prevalent cases
• Idiopathic Pulmonary Fibrosis Gender-specific diagnosed prevalent cases
• Idiopathic Pulmonary Fibrosis Age-specific diagnosed prevalent cases
• Idiopathic Pulmonary Fibrosis Severity-specific diagnosed prevalent cases

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends, click here for Idiopathic Pulmonary Fibrosis epidemiology segmentation @https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Idiopathic Pulmonary Fibrosis Marketed Drugs

• ESBRIET (Pirfenidone): Hoffmann-La Roche Ltd

ESBRIET is an orally administered, anti-inflammatory and antifibrotic prescription medicine used for the treatment of mild and moderate cases of IPF in adults. The drug acts by reducing the amount of lung fibrosis by blocking secretions responsible for excessive collagen production and prolonging the patient's survival by slowing the progression of the disease.

• OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH & Co. KG

OFEV is a prescription drug for the treatment of IPF in adults. Nintedanib is the key ingredient and is a kinase inhibitor that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).

Idiopathic Pulmonary Fibrosis Emerging Drugs

• Pamrevlumab: FibroGen

FibroGen is developing Pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases.

• PRM-151 (RG6354): Hoffmann-La Roche Ltd

PRM-151 (RG6354) is an intravenously administered, recombinant human serum amyloid P/pentraxin 2 protein (PTX2) that is being developed by Roche. Pentraxin 2 is an endogenous protein - present in humans - that regulates the fibrosis response. It helps the immune system to naturally reverse and turn off the fibrosis process that may be caused due to excessive secretion of collagen, cellular growth, and differentiation. RG6354 works by healing the fibrotic tissue, unlike other therapies, which tend to direct a single target inhibition.

• Tyvaso (inhaled treprostinil): United Therapeutics

Tyvaso (treprostinil) is a prostacyclin mimetic approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The company is currently evaluating Tyvaso in an ongoing worldwide Phase III clinical trial named TETON 1 for the treatment of patients with IPF.

Idiopathic Pulmonary Fibrosis Market Outlook

Idiopathic pulmonary fibrosis (IPF) is a lung disorder with scarring of the lungs from an unknown cause. It is one of the most aggressive forms of idiopathic interstitial pneumonia (IIPs). The majority of patients are male, and the risk of IPF for someone aged 75 years is eight times that of someone aged 45-54 years. It is reported that without treatment, the median survival in patients with IPF is 2-4 years after diagnosis.

To know more about Idiopathic Pulmonary Fibrosis Medications, visit Idiopathic Pulmonary Fibrosis Ongoing Clinical Trials @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Idiopathic Pulmonary Fibrosis Market Report

• Coverage- Global

• Idiopathic Pulmonary Fibrosis Companies- FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others

• Idiopathic Pulmonary Fibrosis Pipeline Therapies- Pirfenidone, GB0139, Tralokinumab cohort 1, Nalbuphine ER, Pamrevlumab, TRK-250, VAY736, Vismodegib, and others.

• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

To discover more about Idiopathic Pulmonary Fibrosis Market Drugs in development, click here for Idiopathic Pulmonary Fibrosis Market Dynamics and Idiopathic Pulmonary Fibrosis Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
4. Idiopathic Pulmonary Fibrosis Market: Future Perspective
5. Executive Summary of Idiopathic Pulmonary Fibrosis
6. Key Events
7. Disease Background and Overview of Idiopathic Pulmonary Fibrosis
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Idiopathic Pulmonary Fibrosis: Seven Major Market Analysis
13. KOL Views
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Reimbursement and Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

To read more about the Idiopathic Pulmonary Fibrosis Patient Population of the report, click here for Idiopathic Pulmonary Fibrosis Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.